ArticleBlood2017
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 3 syntheses or guidelines pooled it, 280 citations in OpenAlex.
- Guideline
- [Chinese guideline for diagnosis and treatment of hairy cell leukemia (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Guideline
- Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Guideline
- Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood advances · 2021Trial
- Trial
- Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.Blood advances · 2020Trial
- Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.European journal of haematology · 2026Article
- Hairy Cell Leukemia: A Rare Differential for an Infiltrative Pancreatic Mass.ACG case reports journal · 2026Article
- Management of hairy cell leukaemia in pregnancy.Obstetric medicine · 2026Article
- The effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia.Stem cell research & therapy · 2026Article
- Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms.Blood advances · 2026Review
- Understanding hairy cell leukemia in the context of mature B-cell neoplasms: tumor microenvironment and extracellular vesicle contribution to disease pathogenesis.Frontiers in immunology · 2026Review
- Approach to Hairy-Cell Leukemia in the New Therapeutic Era with Special Emphasis on Age and Comorbidities.Acta haematologica · 2026Review
- Precision-guided therapy in dialysis-dependent classic hairy cell leukemia: a case report.Frontiers in oncology · 2026Article
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa.Journal of blood medicine · 2026Article
- Article
- Deferring treatment in hairy cell leukemia: is active surveillance safe?Blood neoplasia · 2025Article
- Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis.Cancer reports (Hoboken, N.J.) · 2025Article
- Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring.British journal of haematology · 2025Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 12 countries.
Funding
Abstract
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.